Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
The company also gave 2011 guidance of 6% to 10% EPS growth. This prompted analysts to revise their estimates higher, sending the stock to a Zacks #2 Rank (Buy).
D&B has also been rewarding its shareholders through stock buybacks and dividend increases. It currently yields 1.6%.
Company Description
The Dun & Bradstreet Corporation provides its customers with business information. The company provides solutions to mitigate credit risk, and to increase revenue, cash flow, and profitability.
Fourth Quarter Results
D&B reported fourth quarter EPS of $1.92, beating the Zacks Consensus Estimate by 2%. It was a 10% increase over the same quarter in 2009.
Core revenue was up 7% year-over-year driven by an 8% increase in Risk Management Solutions. The Sales & Marketing Solutions division was up 6%.
Meanwhile, operating income improved 7%.
Outlook
The company stated in its latest earnings release that it expects 2011 EPS growth of 6% to 10%, which comes out to $6.00 to $6.23 per share.
The Zacks Consensus Estimate is toward the lower end of guidance at $6.01, equating to 6% EPS growth. The 2012 estimate is currently $6.91, or 15% higher than 2011.
It is a Zacks #2 Rank (Buy) stock.
Rewarding Shareholders
D&B generated $249 million in free cash flow in 2010 and expects to generate between $240 million and $270 million in 2011. The company has been using its free cash flow to return value to shareholders through stock repurchases and a dividend increase.
For instance, D&B recently announced that it was raising its quarterly dividend from 35 cents per share to 36 cents. This marks the 4th consecutive year of a dividend hike. It currently yields 1.6%.
The company also spent $134.8 million in 2010 buying back approximately 1.8 million shares.
Valuation
Shares of DNB have jumped nearly 30% since September 1.
Valuation has remained in-check, however, with shares trading at 14.2x forward earnings, a discount to the industry average of 20.0x.
D&B is headquartered in Short Hills, New Jersey and has a market cap of $4.3 billion.
Todd Bunton is the Growth & Income Stock Strategist for Zacks.com.
Read the full Analyst Report on DNB